These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 10561240)

  • 1. Studies on new antiemetic drugs.
    Roila F; Tonato M; Ballatori E; Del Favero A
    J Clin Oncol; 1999 Jun; 17(6):1960-2. PubMed ID: 10561240
    [No Abstract]   [Full Text] [Related]  

  • 2. CJ 11974.
    Drugs R D; 1999 Oct; 2(4):241-2. PubMed ID: 10659398
    [No Abstract]   [Full Text] [Related]  

  • 3. New antiemetic effective for cisplatin-induced emesis.
    Oncology (Williston Park); 1989 Jul; 3(7):79. PubMed ID: 2534945
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation.
    Darmani NA; Zhong W; Chebolu S; Mercadante F
    Pharmacol Biochem Behav; 2015 Apr; 131():104-11. PubMed ID: 25687374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of an antiemetic regimen with a high-dose metoclopramide, dexamethasone and diphenhydramine combination in chemotherapy regimens with cisplatin].
    Abad-Esteve A; Rosell R; Moreno I; Monrás P; Fernández C; Serichol M; Clotet M; Ribas Mundó M
    Med Clin (Barc); 1986 Dec; 87(19):796-8. PubMed ID: 3821231
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C; Slusher BS
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiemetic effect of Xiao-Ban-Xia-Tang, a Chinese medicinal herb recipe, on cisplatin-induced acute and delayed emesis in minks.
    Qian Q; Chen W; Yue W; Yang Z; Liu Z; Qian W
    J Ethnopharmacol; 2010 Apr; 128(3):590-3. PubMed ID: 20097280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress.
    Hesketh PJ
    Oncology (Williston Park); 2004 Sep; 18(10 Suppl 6):9-14. PubMed ID: 15510975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance between substance P levels and antiemetic guidelines.
    Higa GM; Auber ML; Altaha R; Kurian S; Hobbs G
    J Support Oncol; 2009; 7(4):138-42. PubMed ID: 19731580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
    Schwartzberg LS
    Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in the management of chemotherapy-induced emesis: do they impact on existing guidelines?
    Grunberg SM
    Oncology (Williston Park); 2004 Sep; 18(10 Suppl 6):15-9. PubMed ID: 15510976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.
    Navari RM; Aapro M
    N Engl J Med; 2016 Apr; 374(14):1356-67. PubMed ID: 27050207
    [No Abstract]   [Full Text] [Related]  

  • 15. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The control of chemotherapy-induced nausea and vomiting].
    Shinkai T; Saijo N; Sawamura N; Funaki U; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Shimizu E
    Gan No Rinsho; 1985 Jun; 31(7):779-91. PubMed ID: 3897622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
    Navari RM; Reinhardt RR; Gralla RJ; Kris MG; Hesketh PJ; Khojasteh A; Kindler H; Grote TH; Pendergrass K; Grunberg SM; Carides AD; Gertz BJ
    N Engl J Med; 1999 Jan; 340(3):190-5. PubMed ID: 9917226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The antiemetic activity of buspirone].
    Naletov SV; Stoianov IuB; Kharin NA
    Lik Sprava; 1992 Sep; (9):58-9. PubMed ID: 1481507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiemetic drugs.
    Cranwell-Bruce L
    Medsurg Nurs; 2009; 18(5):309-13; quiz 314. PubMed ID: 19927970
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparative study of an antiemetic NK1 receptor-antagonist in lung cancer patients treated with divided doses for Cisplatin].
    Sato H; Wada K; Umehara K; Otsu K; Wakamoto A; Hatsuyama T; Fujita A; Sekine K
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):733-6. PubMed ID: 23863648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.